CRDF Q4 2021 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$139M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$133,000+11.5% YoY

Gross Profit

$133,000100.0% margin

Operating Income

-$10M-7162.4% margin

Net Income

-$9M-7099.2% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+54.7%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$990,000

Balance Sheet

Total Assets

$150M

Total Liabilities

$9M

Stockholders' Equity

$140M

Cash & Equivalents

$12M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$133,000	$119,255	+11.5%
Gross Profit	$133,000	$119,255	+11.5%
Operating Income	-$10M	-$6M	-46.6%
Net Income	-$9M	-$7M	-43.1%